{"findings":[{"claimIds":["C1"],"code":"PROFILE_FIELD_RESTATEMENT","evidenceIds":["ev-54343b077a33e039b3a4a0b795a33ae0741442ddfdf57958b684a6accb6f84b8","ev-625978e55e235393f924c2e318d2719d442f8dbb4c303d42744eac77a938f3e5","ev-10ea081c1d4ce5d21da7b366caba15ed185c103fa10706ccbc59178341f15d0c"],"explanation":"C1 restates the profile's own /fields and /keywords lists (E065: Bioinformatics, HPC, Genomics, Cloud Computing; E077: read alignment, variant calling, pipeline parallelisation, cloud cost optimisation). It is labelled as a profile self-description and flagged in limitations as unverified against deliverables, which is the correct epistemic status: profile keywords alone are not evidence of performed work. The surrounding claims (C3/E023, C4/E048, C5/E030) carry the actual attributable content, so the draft does not rest the technical case on E065/E077 alone. No correction required beyond keeping the stated limitation.","id":"CK-01","recheckQuestion":"Does any draft section treat the E065/E077 keyword lists as performed-work evidence rather than as a self-described profile?","scope":"claim","severity":"advisory"},{"claimIds":["C2"],"code":"PROJECT_CAPABILITY_NOT_DELIVERY","evidenceIds":["ev-c7e8de2c805b759e633e2f6328735e9f087252e1884af5370d37272fa10162f5","ev-5f1f974c5f0df9b942354f61a09d05cf882becdcd97f0825ff9f33df178b195e"],"explanation":"C2 describes SYN-PRJ-0254 (GENOMFLO) accurately: E158 states the project 'develops and validates' a cloud-cost-aware orchestration layer and that 'pilot deployments are planned at two regional clinical partners', and E071 confirms R0123 is a listed participant (role 'principal investigator'). The claim is worded in present/development terms and the limitations explicitly note that no completed-deployment results exist. The technicalRationale sentence linking GENOMFLO to the company's two-person bioinformatics setup is a resemblance statement, not a claim of validated deployment at scale, so it stays within the source. The draft does not claim that GENOMFLO results are transferable or delivered.","id":"CK-02","recheckQuestion":"Is GENOMFLO ever cited as a completed, validated deployment rather than a project under development with planned pilots?","scope":"claim","severity":"advisory"},{"claimIds":["C3","C8"],"code":"QUANTITATIVE_TRANSFER_LIMITS","evidenceIds":["ev-17eb6d3e27a3376b2f2e3e4d515dba94c575628055a59c5a949a8afe31768b2f"],"explanation":"C3 reproduces E023 faithfully: cost model over 500 synthetic cohort scenarios (50–1000 samples, 10×–30× coverage), naive spot use without checkpointing raising effective cost 18–34% in high-volatility markets, and a bidding-plus-checkpoint strategy cutting cost 41% versus on-demand in stable periods, validated against billing records of a 200-sample pilot. The qualifications that matter are already present: C3 limitations note the WGS/WES coverage regime and market volatility, C8 limitations note the panel-vs-WES transfer assumption and interruption risk, and the run constraints section states that these figures 'are not guarantees for a targeted star-allele panel'. C3 does not assert that 41% alone closes the 9 EUR to <3 EUR (67%) gap; C7 correctly inserts a profiling and calibration phase as the first step. This is an honestly bounded inference rather than an overstated guarantee.","id":"CK-03","recheckQuestion":"Does any claim or section present the 41% spot figure (or the 4.1h-to-41min figure) as a guaranteed outcome for GenovaMed's 24-sample star-allele batches?","scope":"claim","severity":"advisory"},{"claimIds":["C4","C8"],"code":"CONCORDANCE_SCOPE","evidenceIds":["ev-386ebffa1089ce50395b10e140c2bf00d9432f00b34aeb4c55f9d96b8cbee020","ev-6d8d59a890ebaab690cdd83583375e0c20744530a7560717c74f0deddebb53fc"],"explanation":"C4 matches E048 exactly (412 WES samples, mean 85×; scatter–gather reduced mean per-sample runtime 4.1 h to 41 min on 32 cores; SNP precision 99.91%/recall 99.87%, indel 99.34%/99.21% against baseline on GIAB variants) and E082 confirms R0123 is author index 3 on that paper. The draft does not upgrade the internal concordance check into independent clinical validation: C4 limitations say so explicitly, and the validation section proposes an accuracy gate measured against the company's own current calls on retained ethics-approved samples — which is the appropriate comparison for 'without touching clinical accuracy'. Note the 41-minute figure is stated for a 32-core configuration and 85× WES, so the sub-90-minute goal is stated as a target to be tested, not as achieved.","id":"CK-04","recheckQuestion":"Is the E048 concordance result ever described as clinical validation of star-allele calls, or used to assert the under-90-minute target as already met?","scope":"claim","severity":"advisory"},{"claimIds":["C5"],"code":"SELF_REPORTED_EXPERIENCE","evidenceIds":["ev-226e5222e55fdfeb9a9aa56e0f49f3737b4529536d32a22e8158d3bfed47f3f4"],"explanation":"C5 quotes E030 precisely, including the 'approximately 35%' hedge and the three-month 2023 engagement on a cloud-based WES pipeline. C5 is labelled kind 'fact' but its limitations correctly identify it as a self-reported profile field with no client reference, baseline figures or independent verification. That is the only registered evidence of a prior comparable commercial engagement in the selected bundle, and it is directly on the challenge's core need (cloud cost of a sequencing pipeline), so citing it is proper — provided it remains framed as self-reported and WES-scoped, which it is.","id":"CK-05","recheckQuestion":"Is the 35% figure presented anywhere as audited or guaranteed rather than a self-reported profile statement?","scope":"claim","severity":"advisory"},{"claimIds":["C6","C7","C8"],"code":"HYPOTHESIS_BOUNDING","evidenceIds":["ev-17eb6d3e27a3376b2f2e3e4d515dba94c575628055a59c5a949a8afe31768b2f","ev-386ebffa1089ce50395b10e140c2bf00d9432f00b34aeb4c55f9d96b8cbee020","ev-756362a0e60229f6e2fa04f25c74f98b4647f4985d053fae0527384acb43b07d","ev-b883d6b162209ccffcea999a4f248970d03cc2988f8946f05ca2ee73c3871e94","ev-c7e8de2c805b759e633e2f6328735e9f087252e1884af5370d37272fa10162f5"],"explanation":"C6 is honestly typed 'inference' and its limitations state that neither party has measured this pipeline and that the mapping is by analogy until per-step profiling is done; the unknowns section repeats that the sub-3-EUR and under-90-minute targets remain untested hypotheses. C7 begins with instrumentation and cost-model calibration before any code optimisation, which is the correct posture given the company has not profiled bottlenecks. C8's targeted optimisation phase cites E048 (scatter–gather, sample-level parallelism), E023 (checkpointed spot bidding) and E142 (aligner runtime/RAM trade-offs) as method sources rather than as validated results for panels. Mapping is by capability, and all transfer assumptions are disclosed.","id":"CK-06","recheckQuestion":"Does the draft ever assert that the sub-3-EUR or under-90-minute targets have been demonstrated, rather than proposed as bounded hypotheses?","scope":"claim","severity":"advisory"},{"claimIds":["C9"],"code":"IDENTITY_LIMITS_DISCLOSED","evidenceIds":["ev-c7e8de2c805b759e633e2f6328735e9f087252e1884af5370d37272fa10162f5","ev-17eb6d3e27a3376b2f2e3e4d515dba94c575628055a59c5a949a8afe31768b2f","ev-386ebffa1089ce50395b10e140c2bf00d9432f00b34aeb4c55f9d96b8cbee020"],"explanation":"C9 correctly notes unresolved co-author/co-participant identities and draws no conclusion about their affiliations or endorsement. R0123's own ID is bound through explicit relations: author index 0 on SYN-PUB-01615 (E021) and SYN-PUB-01617 (E005), author index 3 on SYN-PUB-01614 (E082), participant on SYN-PRJ-0254 (E071). The author positions are not used to claim lead authorship of the cost/throughput work; the cost-model paper is first-authored by R0123 and C3 does not overstate the role on the two co-authored papers. This matches Counter CE-10.","id":"CK-07","recheckQuestion":"Is any author position used to assert a specific technical contribution not supported by the abstract content?","scope":"claim","severity":"advisory"},{"claimIds":["C10"],"code":"PARTICIPATION_SCOPE_RESPECTED","evidenceIds":["ev-51a912e3c4cc6026d4b2e03aa571708f3b6c2b9c32a275d354e47e28c4bfe9db","ev-730c8d9381c57c0bd5c7a3f5044e4621d32878f8022ab5fcef6c0158c7fd7baa","ev-226e5222e55fdfeb9a9aa56e0f49f3737b4529536d32a22e8158d3bfed47f3f4"],"explanation":"C10 quotes E088 (joint projects, contract research, consulting, student internships) and E060 (interest in partners facing concrete genomic cost/throughput constraints; not theoretical or database-curation work). Both conditions are satisfied by this challenge: GenovaMed is a genomic data processor with an explicit cost and turnaround problem, and the draft proposes time-boxed contract research/consulting, not a database-curation collaboration. The constraints section correctly separates 'preferences support' from undocumented availability, fees, IP terms and data-processing agreements. No availability or capacity is inferred upward from the profile. The Counter report found no restriction conflict for R0123, and nothing in the draft claims guaranteed availability.","id":"CK-08","recheckQuestion":"Does the draft infer availability, fees or IP terms beyond what E060/E088/E030 state, or propose an engagement form outside the listed open_to categories?","scope":"claim","severity":"advisory"},{"claimIds":[],"code":"POOL_SELECTION_SOUNDNESS","evidenceIds":["ev-0221b9290d846d30e49a3299527df4b9476badb25fa74a0412a094e15b86870e","ev-5818758a94b4c6e25d9eacb0266405fcdfa4ab4346d5a72fc4162c0575e5f392","ev-ddca91dce2605edda549935ad08b5bc8bfaffd211d995e6f098979ea22575052","ev-e0729c8443c593abed3077606767f7eb2dcee1b9308d38b1f806ea6c22649a1a","ev-07083e638a8b62605368bb23b359b912bb0b66c4158cb41d986606744dbe6425"],"explanation":"The draft correctly centers on R0123 as the pair under review. The remaining pool candidates do not offer registered content on sequencing pipeline cost or star-allele calling: R0945 (electronics CoQ, E111/E191/E120 open_to electronics-only), R1005 (fermentation microbiology, E070/E172), R0775 (textile nesting, E047/E094/E068), R0751 (hospitality pricing, E185/E119), R0633 (job-shop pricing, E069/E026), R0781 (plant-omics/Bayesian networks, E175/E013), R0595 (clinical tabular ML plus a synthetic-price-spot model, E031/E159). Nothing in the draft borrows support from a different partner or proposes work outside the fixed pool. The absence of a candidate with pharmacogene diplotype calling (Counter CE-08) is a pool-level gap, not a defect in this pair's proposal, and does not by itself defeat cooperation suitability because the challenge's stated need is cost and runtime optimisation of an existing, correctly functioning pipeline rather than rebuilding calling accuracy.","id":"CK-09","recheckQuestion":"Does any section attribute technical support to a researcher other than the selected partner R0123, or otherwise rely on evidence outside the fixed pool?","scope":"run","severity":"advisory"}],"hash":"edaa97dcedbc413ad1df2ddc47ff422537b013508400d3a2b35a3b9bed3e0739","id":"review_89280b42-02b4-46db-9a84-ab0c80eeb543","runId":"d80bfe16-3fe3-4cfa-8334-e8b51bf4b425","target":{"counterReportHash":"ebe3672d16b80e64055f6c8647763deaa9ff8a7ad8693b22d27a071323dc6f21","draftHash":"0875fe11f66c492aa131446feb9a336df5d3b07bb091f7e3bdd13f8058471a7c","draftVersion":1,"evidenceSnapshotHash":"368f6673a0f5f19e92d3dc418b435fe92d6da6281121527fbb75cdb1a6ea03cd","inputHash":"097202fa360dab5b7a51a0939ceb8a2f489b990c744415053ff3ef8aa01e0aa1","poolHash":"9a759b6d44a3d8b1cf39f3c28e898c6ad37b7d87edda375467353381515c941a","poolVersion":1},"verdict":"approve","version":1}